Revolutionizing Kidney Disease Treatment: Purespring Therapeutics Raises £80 Million in Series B Funding Round

Purespring Therapeutics, a pioneering company dedicated to revolutionizing kidney disease treatment, has successfully raised £80 million in its latest funding round. Launched in November 2020 with an initial investment of £45 million from Syncona Ltd, Purespring stands out as the first company to focus on targeting podocytes—specialized kidney cells that play a crucial role in various kidney diseases—through innovative AAV (adeno-associated virus) gene therapy. This groundbreaking approach is rooted in the transformative research of Professor Moin Saleem, a leader in the field of Paediatric Renal Medicine at the University of Bristol. Professor Saleem's team is recognized globally for its contributions to understanding glomerular diseases, and their work serves as the foundation for Purespring's therapeutic strategies. The fresh influx of £80 million will be instrumental in accelerating Purespring’s mission to develop effective treatments for kidney ailments by advancing their genetic therapies into clinical trials. The funding will also bolster the company’s research efforts, enabling it to explore new avenues for treating podocyte-related disorders and expand its pipeline of innovative solutions. As Purespring moves forward, the company remains committed to improving the lives of patients affected by chronic kidney diseases, further solidifying its position at the forefront of renal research and therapeutic development.